Details for Patent: 8,993,636

Title:	Compositions containing moxifloxacin for treating otic infections
Abstract:	Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
Inventor(s):	Cagle; Gerald (Fort Worth, TX), Abshire; Robert L. (Fort Worth, TX), Stroman; David W. (Irving, TX), Yanni; John M. (Burleson, TX)
Assignee:	Alcon Pharamceuticals, Ltd. (Fribourg, CH)
Filing Date:	Oct 25, 2013
Application Number:	14/062,957
Claims:	1. A pharmaceutical product in multidose form comprising (i) a topical otic pharmaceutical composition comprising moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of 0.35 to 1.0 wt. % and a pharmaceutically acceptable vehicle therefor, and (ii) instructions for topically applying the composition to otic tissue. 2. A pharmaceutical product according to claim 1, wherein the composition further comprises an anti-inflammatory effective amount of a steroidal or non-steroidal anti-inflammatory agent. 3. A pharmaceutical product according to claim 2, wherein the anti-inflammatory agent comprises a glucocorticoid. 4. A pharmaceutical product according to claim 3, wherein the glucocorticoid is selected from the group consisting of dexamethasone, rimexolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone and budesonide. 5. A pharmaceutical product according to claim 2, wherein the anti-inflammatory agent comprises a non-steroidal agent selected from the group consisting of prostaglandin H synthetase inhibitors, PAF antagonists, and PDE IV inhibitors. 6. A pharmaceutical product according to claim 2, wherein the compound of formula (I) comprises moxifloxacin or a pharmaceutically useful hydrate or salt thereof. 7. A pharmaceutical product according to claim 2, wherein the anti-inflammatory agent comprises dexamethasone. 8. A pharmaceutical product according to claim 7, wherein the composition contains moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of about 0.35 wt. %. 9. A pharmaceutical product according to claim 2, wherein the anti-inflammatory agent comprises nepafenac. 10. A pharmaceutical product according to claim 9, wherein the composition contains moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of about 0.35 wt. %. 11. A pharmaceutical product according to claim 1, wherein the composition has a pH in a range of 4.5 to 8.0. 12. A pharmaceutical product according to claim 1, wherein the composition has an osmotic value in a range of from about 200 to about 400 milliosmoles per kilogram of water.